Awakn, Revitalist partner to provide ketamine treatment for alcohol use disorders

Awakn Life Sciences Corp. has signed a licensing agreement with Revitalist Lifestyle and Wellness to implement its KARE protocol for those suffering from alcohol use disorder who are seeking sustained recovery and relapse prevention.

In January, the American Journal of Psychiatry published findings from a phase 2 a/b trial of Awakn’s ketamine-assisted therapy for the treatment of alcohol use disorder. Researchers reported a rate of 86% abstinence 6 months post-baseline, compared with 2% pre-baseline and 25% who received the current standard of care.

According to a press release, under the terms of the license agreement, Awakn will provide access to the propriety therapeutics and training by their experts to the Revitalist providers. Revitalist will pay an annual licensing fee and revenue share for clients seeking services through the partnership.

There are more than 14,000 alcohol and substance addiction treatment facilities in the United States, generating more than $30 billion in revenue annually. However, the industry sees a reported 75% relapse rate in the 12 months after treatment, according to the release.